Literature DB >> 10933942

Evaluation of the biodistribution, persistence, toxicity, and potential of germ-line transmission of a replication-competent human adenovirus following intraprostatic administration in the mouse.

D L Paielli1, M S Wing, K R Rogulski, J D Gilbert, A Kolozsvary, J H Kim, J Hughes, M Schnell, T Thompson, S O Freytag.   

Abstract

Adenovirus-mediated gene transfer may hold much promise in the treatment of human cancer. However, concerns regarding vector dissemination beyond the target tissue, particularly with replication-competent viruses, require an evaluation of the persistence of viral infection in collateral tissue and vector-associated toxicities. In addition, for indications such as prostate cancer, the proximity of the point of viral administration to organs of the male reproductive system raises concerns regarding inadvertent germ-line transmission of genes carried by the virus. To address these concerns, the biodistribution, persistence, toxicity, and potential of germ-line transmission of a replication-competent adenovirus (Ad5-CD/TKrep) following intraprostatic administration in the mouse was examined. Ad5-CD/TKrep (10(10) vp, 5 x 10(11) vp/kg) was injected intraprostatically on Day 1 of the study and its presence in the major organs of the male urogenital tract (prostate, testes, seminal vesicles, and urinary bladder) and liver was determined on Days 8 and 29. For comparison, a parallel group of animals was injected with the same dose of a related replication-defective Ad5-FGNR virus. To evaluate germ-line transmission, Ad5-CD/TKrep-injected males were mated to females on Days 8 and 29 and resulting embryos were examined for AdS-CD/TKrep viral DNA. Ad5-CD/TKrep viral DNA was detected in all major organs of the adult male urogenital tract and liver 7 and 28 Days postinjection. Interestingly, relative to the replication-defective Ad5-FGNR adenovirus, the replication-competent Ad5-CD/TKrep virus accumulated to a much greater level (approximately 300-fold) and persisted for a longer period of time in prostate, testes, and liver. This difference could not be explained on the basis of differences in viral infectivity, suggesting that the AdS-CD/TKrep virus may be capable of replicating in mouse tissues in vivo. In vitro infection of six mouse cell lines representing prostate, testes, and liver demonstrated that the Ad5-CD/TKrep virus was indeed capable of replicating in these mouse cell types, albeit with reduced efficiencies relative to human cells. Despite the fact that the Ad5-CD/TKrep vector persisted in the adult male gonads and may have replicated in vivo, we observed no evidence of germ-line transmission in 149 offspring examined. To evaluate the toxicity of combining Ad5-CD/TKrep viral therapy with CD/5-FC and HSV-1 TK/GCV suicide gene therapies as a prerequisite for a human trial, an escalating dose (10(8), 10(9), 10(10) vp) of Ad5-CD/TKrep was administered intraprostatically followed by 7 days of 5-FC and GCV double prodrug therapy. Although the virus persisted in the mouse urogenital tract and liver for up to 28 days postinjection, most of the toxicities observed were expected, minimal, and self-limiting. These results lead us to believe that intraprostatic administration of the Ad5-CD/TKrep virus to humans concomitant with double suicide gene therapy will be associated with acceptable toxicities and will not result in vertical transmission of viral-encoded genes through the germ line.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10933942     DOI: 10.1006/mthe.2000.0037

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  19 in total

Review 1.  Gene therapy for prostate cancer.

Authors:  J R Gingrich; R D Chauhan; M S Steiner
Journal:  Curr Oncol Rep       Date:  2001-09       Impact factor: 5.075

Review 2.  Current strategies and future directions for eluding adenoviral vector immunity.

Authors:  Dinesh S Bangari; Suresh K Mittal
Journal:  Curr Gene Ther       Date:  2006-04       Impact factor: 4.391

3.  Antitumor effects of bladder cancer-specific adenovirus carrying E1A-androgen receptor in bladder cancer.

Authors:  Z Zhai; Z Wang; S Fu; J Lu; F Wang; R Li; H Zhang; S Li; Z Hou; H Wang; R Rodriguez
Journal:  Gene Ther       Date:  2012-01-05       Impact factor: 5.250

Review 4.  Adenoviral vector immunity: its implications and circumvention strategies.

Authors:  Yadvinder S Ahi; Dinesh S Bangari; Suresh K Mittal
Journal:  Curr Gene Ther       Date:  2011-08       Impact factor: 4.391

5.  Genomic integration of adenoviral gene transfer vectors following transduction of fertilized mouse oocytes.

Authors:  Nancy Larochelle; Rolf Stucka; Norman Rieger; Lothar Schermelleh; Gudrun Schiedner; Stefan Kochanek; Eckhard Wolf; Hanns Lochmüller
Journal:  Transgenic Res       Date:  2010-05-13       Impact factor: 2.788

6.  Adenovirus-mediated gene delivery into mouse spermatogonial stem cells.

Authors:  Masanori Takehashi; Mito Kanatsu-Shinohara; Kimiko Inoue; Narumi Ogonuki; Hiromi Miki; Shinya Toyokuni; Atsuo Ogura; Takashi Shinohara
Journal:  Proc Natl Acad Sci U S A       Date:  2007-02-13       Impact factor: 11.205

7.  Characterization and real-time imaging of gene expression of adenovirus embedded silk-elastinlike protein polymer hydrogels.

Authors:  Arthur von Wald Cresce; Ramesh Dandu; Angelika Burger; Joseph Cappello; Hamidreza Ghandehari
Journal:  Mol Pharm       Date:  2008-09-03       Impact factor: 4.939

8.  Expanded anticancer therapeutic window of hexon-modified oncolytic adenovirus.

Authors:  Elena V Shashkova; Shannon M May; Konstantin Doronin; Michael A Barry
Journal:  Mol Ther       Date:  2009-09-15       Impact factor: 11.454

9.  Efficacy of oncolytic adenovirus expressing suicide genes and interleukin-12 in preclinical model of prostate cancer.

Authors:  S O Freytag; K N Barton; Y Zhang
Journal:  Gene Ther       Date:  2013-07-11       Impact factor: 5.250

10.  INGN 007, an oncolytic adenovirus vector, replicates in Syrian hamsters but not mice: comparison of biodistribution studies.

Authors:  B Ying; K Toth; J F Spencer; J Meyer; A E Tollefson; D Patra; D Dhar; E V Shashkova; M Kuppuswamy; K Doronin; M A Thomas; L A Zumstein; W S M Wold; D L Lichtenstein
Journal:  Cancer Gene Ther       Date:  2009-02-06       Impact factor: 5.987

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.